JAMA NetworkAllogeneic Hematopoietic Cell Transplantation vs. Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial

The findings of this randomized clinical trial support the notion that, despite improved DFS, patients 60 years or younger with intermediate-risk AML, as defined by Medical Research Council cytogenetic criteria, do not benefit from allo-HCT during first CR in terms of OS. Early identification of a suitable donor allows for the timely rescue of patients who have relapsed following conventional consolidation chemotherapy. Future research that uses longitudinal monitoring of residual disease dynamics will aid in personalizing the optimal time point for allo-HCT in the majority of patients.